KCNQ2 COVID-19 Emergency Relief Grant Program

By KCNQ2 Cure on May 31, 2020



KCNQ2 COVID-19 Emergency Relief Grant Program

We at the KCNQ2 Cure Alliance have spent the last few months split between wrangling our own families (who knew 2020 would give us the opportunity to try out being full-time chefs, teachers, coaches, nurses, and teleworkers all at once?) and thinking about our KCNQ2 community. In early May, the global KCNQ2 family was set to descend upon Philadelphia, Pennsylvania, for three days of learning, connecting, and recharging our community’s collective batteries.

COVID-19 had other plans.

And as the huge toll of the pandemic came crashing down on our community, we wanted to act fast to lessen, even just a little, the weight of what many of our families were experiencing. To name just a few: full-time caregiving, stocking up on supplies and medicines in the face of disrupted supply chains, and financial uncertainty and hardship of all stripes.

That’s why we started the KCNQ2 COVID-19 Emergency Relief Grant Program, to quickly get funds to KCNQ2 families around the world who were navigating incredibly challenging times with less support than ever.

We’re pleased to share that in our first round of funding, we awarded 19 grants to families in 5 countries, for a total of $9,300.

But we’re even more excited to share that we are just getting started!

Thanks to a generous donation from Xenon Pharmaceuticals, we are delighted to announce a second round of funding that will open June 1, 2020, and run until June 19, 2020.

Xenon is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders and rare central nervous conditions including KCNQ2, and we are proud to partner with them to support KCNQ2 families around the world.

Learn more and view the application click here.

Posted in ,

KCNQ2 Cure


Sign up for our KCNQ2 Connections blog for updates on research, events, and happenings in the KCNQ2 community.



Follow Us On